Clinical Trial Update: Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD. [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy and safety of adding Symbicort to Spiriva in patients with severe COPD. The trial results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, COPD | Phase 4 | Status: COMPLETED | Results posted: 2012-11-09